ANI Pharmaceuticals (NASDAQ:ANIP) Stock Price Passes Below 200 Day Moving Average of $61.19

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)’s stock price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $61.19 and traded as low as $58.45. ANI Pharmaceuticals shares last traded at $58.53, with a volume of 324,176 shares changing hands.

Wall Street Analyst Weigh In

ANIP has been the topic of several recent analyst reports. Guggenheim reaffirmed a “buy” rating and set a $77.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday, April 23rd. Truist Financial increased their price objective on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. HC Wainwright raised their target price on ANI Pharmaceuticals from $83.00 to $87.00 and gave the stock a “buy” rating in a report on Monday, May 13th. Finally, Capital One Financial initiated coverage on shares of ANI Pharmaceuticals in a report on Friday, March 15th. They set an “overweight” rating and a $80.00 price target on the stock. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $81.00.

ANI Pharmaceuticals Trading Down 1.4 %

The firm has a market cap of $1.23 billion, a price-to-earnings ratio of 36.58 and a beta of 0.81. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.95 and a quick ratio of 3.12. The company’s 50 day simple moving average is $64.38 and its 200 day simple moving average is $61.19.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, May 10th. The specialty pharmaceutical company reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.16. The company had revenue of $137.43 million for the quarter, compared to the consensus estimate of $125.01 million. ANI Pharmaceuticals had a net margin of 6.87% and a return on equity of 17.15%. As a group, research analysts expect that ANI Pharmaceuticals, Inc. will post 3.34 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 16,669 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $66.10, for a total value of $1,101,820.90. Following the completion of the sale, the chief executive officer now owns 377,505 shares in the company, valued at $24,953,080.50. The sale was disclosed in a document filed with the SEC, which is available through this link. In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 16,669 shares of ANI Pharmaceuticals stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $66.10, for a total value of $1,101,820.90. Following the transaction, the chief executive officer now directly owns 377,505 shares in the company, valued at approximately $24,953,080.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Chad Gassert sold 20,000 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $67.25, for a total value of $1,345,000.00. Following the sale, the senior vice president now directly owns 253,226 shares of the company’s stock, valued at $17,029,448.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 156,688 shares of company stock valued at $10,230,863. 12.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Large investors have recently modified their holdings of the business. Texas Permanent School Fund Corp lifted its stake in shares of ANI Pharmaceuticals by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 13,194 shares of the specialty pharmaceutical company’s stock valued at $912,000 after purchasing an additional 172 shares during the period. New York State Teachers Retirement System lifted its position in shares of ANI Pharmaceuticals by 0.9% during the 4th quarter. New York State Teachers Retirement System now owns 22,380 shares of the specialty pharmaceutical company’s stock valued at $1,234,000 after acquiring an additional 200 shares during the period. California State Teachers Retirement System boosted its stake in shares of ANI Pharmaceuticals by 1.5% during the 1st quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company’s stock worth $1,118,000 after acquiring an additional 233 shares in the last quarter. ProShare Advisors LLC grew its holdings in shares of ANI Pharmaceuticals by 10.0% in the 1st quarter. ProShare Advisors LLC now owns 4,447 shares of the specialty pharmaceutical company’s stock worth $307,000 after acquiring an additional 404 shares during the period. Finally, Yousif Capital Management LLC increased its stake in ANI Pharmaceuticals by 8.4% in the 4th quarter. Yousif Capital Management LLC now owns 8,574 shares of the specialty pharmaceutical company’s stock valued at $473,000 after purchasing an additional 668 shares in the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.